Stage T1-T2 prostate cancer with pretreatment prostate-specific antigen level ≤ 10 ng/ml: radiation therapy or surgery? Int J Radiat Oncol Biol Phys. 1997;38:723-729.Stage T1-2prostate cancer with pretreatment prostate-specific antigen level·10ng/ml:radiation therapy or surgery·. Keyser D,...
CancerMatzkin H, Soloway MS, Schellhammer PF, et al. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteriodal antiandrogen. Cancer 1993;72: 1286-90.Matzkin H, Soloway MS, Schellhammer PF, Chodak G, Smith JA, Caplan R and Kennealey GT: Prognostic factors in sta...
Sixty-four patients with Stage T2a prostate adenocarcinoma were identified from the series of prostate patients receiving conformal outpatient brachytherapy between 1990 and 1997. Pretreatment Gleason scores and prostate specific antigen (PSA) values ranged from 2 to 10 and 1.5 to 100, respectively. ...
In the present study, we assessed the relationship of serum insulin levels and three surrogate markers of recurrence, T stage, PSA, and Gleason score, in men with localized prostate cancer. Participants in our study were found through urology and radiation oncology clinics, and all eligible patien...
Article: Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage
Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014;106(2):djt430. doi:10.1093/jnci/djt430PubMedGoogle Scholar 5. Frattaroli J, Weidner G, Dnistrian AM, et al. Clinical events in prostate cancer lifestyle...
Background: African-American men have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced stage at diagnosis, an... Ian,M.,Thompson,... - 《Journal of the National Cancer Institute》 被引量: 389发表: 2001年 Stage at diagnosis of prostate cancer in...
The prognostic value was determined of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) measured before and after endocrine treatment in 57 patients with newly diagnosed Stage D2 prostatic cancer.Methods. Therapy included orchiectomy or administration of luteinizing hormone releasing ...
aMonitoring with PSA after treatment for prostate cancer is a mainstay of clinical practice, although the clinical utility of PSA is variable and depends on the disease stage of the indi-vidual patient. As has recently been observed, the lack of high quality information and paucity of clinical...
I am absolutely confident that we can save people from dying of prostate cancer, but also minimize morbidity. Not every man automatically needs treatment. TARGETED ONCOLOGY:In that trial’s control arm, where 90% of patients did get a PSA, what was the reasoning they did so? Eggener...